| 2024年年报 | 2024年中报 | 2023年年报 | 2023年中报 | |
|---|---|---|---|---|
| 营业收入(元) | ||||
| 传染病类(元) | 366,313,736.80 | 166,266,900.00 | 275,282,593.68 | 126,820,000.00 |
| 毒品及药物滥用类(元) | 231,686,879.42 | 102,314,200.00 | 203,779,061.31 | 93,652,700.00 |
| 妇女健康类(元) | 76,388,849.84 | 35,977,700.00 | 70,914,960.20 | 37,660,900.00 |
| 新冠单检产品收入(元) | - | 25,800,200.00 | - | 69,382,200.00 |
| 肿瘤标志物检测产品收入及心肌标志物检测产品收入(元) | - | 20,264,000.00 | - | 16,013,000.00 |
| 心肌类(元) | 13,850,321.83 | - | 13,413,055.14 | - |
| 新冠检测类(元) | 57,190,689.84 | - | 89,027,106.01 | - |
| 肿瘤类(元) | 32,670,488.34 | - | 19,901,885.27 | - |
| 其他类(元) | 84,266,809.83 | 44,470,100.00 | 79,937,598.74 | 41,366,200.00 |
| 营业成本(元) | ||||
| 传染病类(元) | 168,873,814.46 | - | 150,450,140.38 | - |
| 毒品及药物滥用类(元) | 81,602,800.88 | - | 79,218,564.65 | - |
| 妇女健康类(元) | 49,266,230.28 | - | 62,159,221.24 | - |
| 新冠单检产品收入(元) | - | - | - | - |
| 肿瘤标志物检测产品收入及心肌标志物检测产品收入(元) | - | - | - | - |
| 心肌类(元) | 3,803,499.52 | - | 4,937,190.20 | - |
| 新冠检测类(元) | 32,897,570.01 | - | 40,227,314.62 | - |
| 肿瘤类(元) | 10,659,999.13 | - | 10,844,318.18 | - |
| 其他类(元) | 34,442,415.31 | - | 38,276,037.77 | - |
| 毛利(元) | ||||
| 传染病类(元) | 197,439,922.34 | - | 124,832,453.30 | - |
| 毒品及药物滥用类(元) | 150,084,078.54 | - | 124,560,496.66 | - |
| 妇女健康类(元) | 27,122,619.56 | - | 8,755,738.96 | - |
| 新冠单检产品收入(元) | - | - | - | - |
| 肿瘤标志物检测产品收入及心肌标志物检测产品收入(元) | - | - | - | - |
| 心肌类(元) | 10,046,822.31 | - | 8,475,864.94 | - |
| 新冠检测类(元) | 24,293,119.83 | - | 48,799,791.39 | - |
| 肿瘤类(元) | 22,010,489.21 | - | 9,057,567.09 | - |
| 其他类(元) | 49,824,394.52 | - | 41,661,560.97 | - |
| 毛利率(%) | ||||
| 传染病类(%) | 53.90 | - | 45.35 | - |
| 毒品及药物滥用类(%) | 64.78 | - | 61.13 | - |
| 妇女健康类(%) | 35.51 | - | 12.35 | - |
| 新冠单检产品收入(%) | - | - | - | - |
| 肿瘤标志物检测产品收入及心肌标志物检测产品收入(%) | - | - | - | - |
| 心肌类(%) | 72.54 | - | 63.19 | - |
| 新冠检测类(%) | 42.48 | - | 54.81 | - |
| 肿瘤类(%) | 67.37 | - | 45.51 | - |
| 其他类(%) | 59.13 | - | 52.12 | - |
| 收入构成(%) | ||||
| 传染病类(%) | 42.48 | 42.08 | 36.59 | 32.95 |
| 毒品及药物滥用类(%) | 26.87 | 25.90 | 27.09 | 24.33 |
| 妇女健康类(%) | 8.86 | 9.11 | 9.43 | 9.78 |
| 新冠单检产品收入(%) | - | 6.53 | - | 18.03 |
| 肿瘤标志物检测产品收入及心肌标志物检测产品收入(%) | - | 5.13 | - | 4.16 |
| 心肌类(%) | 1.61 | - | 1.78 | - |
| 新冠检测类(%) | 6.63 | - | 11.83 | - |
| 肿瘤类(%) | 3.79 | - | 2.65 | - |
| 其他类(%) | 9.77 | 11.26 | 10.63 | 10.75 |
| 毛利构成(%) | ||||
| 传染病类(%) | 41.06 | - | 34.09 | - |
| 毒品及药物滥用类(%) | 31.21 | - | 34.02 | - |
| 妇女健康类(%) | 5.64 | - | 2.39 | - |
| 新冠单检产品收入(%) | - | - | - | - |
| 肿瘤标志物检测产品收入及心肌标志物检测产品收入(%) | - | - | - | - |
| 心肌类(%) | 2.09 | - | 2.31 | - |
| 新冠检测类(%) | 5.05 | - | 13.33 | - |
| 肿瘤类(%) | 4.58 | - | 2.47 | - |
| 其他类(%) | 10.36 | - | 11.38 | - |